• Abstract and Figures
• Public Full-text

Hindawi Publishing Corporation Journal of Analytical Methods in Chemistry Volume 2017, Article ID 6749087, 7 pages http://dx.doi.org/10.1155/2017/6749087 Research Article Simultaneous Determination of Dexamethasone, Ondansetron, Granisetron, Tropisetron, and Azasetron in Infusion Samples by HPLC with DAD Detection Fu-chao Chen,1 Lin-hai Wang,2 Jun Guo,3 Xiao-ya Shi,1 and Bao-xia Fang1 1 Department of Pharmacy, Dongfeng Hospital, Hubei University of Medicine, Shiyan, Hubei 442008, China 2Department of Pharmacy, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, China 3Department of Oncology, Dongfeng Hospital, Hubei University of Medicine, Shiyan, Hubei 442008, China Correspondence should be addressed to Bao-xia Fang; [email protected] Received 21 October 2016; Accepted 19 December 2016; Published 11 January 2017 Academic Editor: Chih-Ching Huang Copyright © 2017 Fu-chao Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. A simple and rapid high-performance liquid chromatography with diode array detector (HPLC-DAD) method has been developed and validated for simultaneous quantification of five antiemetic agents in infusion samples: dexamethasone, ondansetron, granisetron, tropisetron, and azasetron. The chromatographic separation was achieved on a Phenomenex18 C column (4.6 mm × 150 mm, 5 m) using acetonitrile-50 mM KH2PO4 buffer-triethylamine (25 : 74 : 1; v/v; pH 4.0). Flow rate was 1.0 mL/min witha ∘ column temperature of 30 C. Validation of the method was made in terms of specificity, linearity, accuracy, and intra- and interday precision, as well as quantification and detection limits. The developed method can be used in the laboratory to routinely quantify dexamethasone, ondansetron, granisetron, tropisetron, and azasetron simultaneously and to evaluate the physicochemical stability of referred drugs in mixtures for endovenous use. 1. Introduction prepared in the hospital pharmacy departments for clinical use. Dexamethasone (DEX) (Figure 1(a)), a synthetic corticos- teroid, has long been used as antiemetic agent in patients From the literature survey it is evident that various undergoing cancer chemotherapy [1, 2], being effective for analytical methods were available for the determination of both acute and delayed nausea and vomiting. Selective 5- DEX, OND, GRA, TRO, and AZA with other combinations hydroxytryptamine type 3 (5-HT3)receptorantagonists, by using high-performance liquid chromatography (HPLC) including ondansetron (OND) (Figure 1(b)), granisetron [11–31]. No method has been reported in the literature for (GRA) (Figure 1(c)), tropisetron (TRO) (Figure 1(d)), and simultaneous estimation of DEX, OND, GRA, TRO, and AZA azasetron (AZA) (Figure 1(e)), are effective and potent in infusion samples. Hence, the objective of the current study antiemetic drugs which are recommended by clinical prac- was to develop and validate a simple, rapid, accurate, and tice guidelines for patients undergoing surgery and cancer precise HPLC method for simultaneous estimation of DEX, chemotherapy [3–6]. Literature survey has revealed that OND, GRA, TRO, and AZA in infusion samples. coadministration of antiemetics from different classes could be a more effective antiemetic treatment modality, and DEX 2. Experimental is a standard component of antiemetic combination regimens with 5-HT3 antagonists [3, 7–10]. Hence, mixtures of 5-HT3 2.1. Chemicals and Reagents. The working standards of DEX receptor antagonists, alone or in combination with DEX, sodium phosphate, OND hydrochloride, GRA hydrochlo- are often used in clinical practice to relieve chemotherapy ride, TRO hydrochloride, and AZA hydrochloride were pur- induced nausea and vomiting. However, there are no com- chased from the National Institutes for Food and Drug Con- ∘ mercially available such drug mixtures, and they must be trol (Beijing, China) and stored at 4 C. The pharmaceutical 2 Journal of Analytical Methods in Chemistry OH N O N N HO O OH O N O HN N F HN N O OH N (a) (b) (c) (d) N O NH O Cl N O (e) Figure 1: Chemical structure of DEX (a), OND (b), GRA (c), TRO (d), and AZA (e). formulations used in this study were DEX sodium phos- flow rate of the mobile phase was kept at 1.0 mL/min. The phate injection 5 mg/1 mL (Cisen Pharmaceutical Co., Ltd., selected detection wavelengths for DEX, OND, GRA, TRO, Shandong, China), OND hydrochloride injection 4 mg/2 mL and AZA were 241 nm, 310 nm, 302 nm, 285 nm, and 302 nm, ∘ (Qilu Pharmaceutical Co., Ltd., Shandong, China), GRA respectively. The assay was performed at 30 C and injection hydrochloride injection 3 mg/3 mL (Cinkate Pharmaceutical volume was 20 L. Corporation, Suzhou, China), TRO hydrochloride injection 5 mg/1 mL (Qilu Pharmaceutical Co., Ltd., Shandong, China), 2.3. Preparation of Stock and Working Solutions. We accu- and AZA hydrochloride injection 10 mg/2 mL (Wanma Phar- rately weighed and transferred 20 mg of DEX sodium maceutical Co., Ltd., Zhejiang, China). The solution of 0.9% phosphate, 16 mg of OND hydrochloride, 12 mg of GRA NaCl used to prepare the sample mixtures was from Kelun hydrochloride, 10 mg of TRO hydrochloride, and 20 mg of Pharmaceutical Co., Ltd. (Sichuan, China). Potassium dihy- AZAhydrochlorideworkingstandardintoa100mLvolumet- drogen phosphate KH2PO4, triethylamine, and phosphoric ric flask. We added about 70 mL of deionised water and used acid of AR Grade were obtained from Xilong Chemical sonication for dissolving completely and made volume up to Ltd. (Guangdong, China). HPLC grade acetonitrile was the mark with the same solvent to obtain the final concen- purchased from Fisher Scientific International (St Louis, MO, tration of 0.2 mg/mL of DEX sodium phosphate, 0.16 mg/mL USA). Ultrapure water was purified using a Milli-Q system of OND hydrochloride, 0.12 mg/mL of GRA hydrochloride, 0.1 mg/mL of TRO hydrochloride, and 0.2 mg/mL of AZA (Millipore, Bedford, MA, USA). ∘ hydrochloride, respectively. The solutions were kept at –20 C 2.2. HPLC Instrumentation and Chromatographic Conditions. until use. Fresh working standard solutions were prepared An UltiMate5 3000 standard high pressure liquid chromato- by diluting the stock solution with deionised water to the graphic instrument (Dionex, Germany) composed of an Ulti- required concentrations before use. Mate 3000 quaternary gradient pump, an ASI-100 autosam- 2.4. Preparation of Infusion Samples. In order to mimic a pler, a TCC-100 thermostat column oven, and an ultraviolet concentration range relevant to clinical practice and the detector (DAD) was employed in the study. Data acquisition conditions commonly occurring in hospitals, four sample was carried out using Chromeleon5 software. Chromato- infusion solutions were prepared under aseptic conditions in graphic analyses were performed on a Phenomenex C18 column (4.6 mm × 150 mm, 5 m)andusingthemobile laminar flow hoods. phase of acetonitrile-50 mM KH2PO4 buffer-triethylamine Solution 1. 2 mL (10 mg) DEX sodium phosphate injectable (25 : 74 : 1; pH adjusted to 4.0 using diluted phosphoric acid). solution and 4 mL (8 mg) OND hydrochloride injectable The mobile phase was prepared daily and filtered through solution were transferred to a 100 mL polyolefin bags and a0.22m membrane filter (Millipore Corp., USA). The filled with 0.9% sodium chloride injection. Journal of Analytical Methods in Chemistry 3 Solution 2. 2 mL (10 mg) DEX sodium phosphate injectable 200 WVL: 241 nm solution and 3 mL (3 mg) GRA hydrochloride injectable 175 solution were transferred to a 100 mL polyolefin bags and 150 filled with 0.9% sodium chloride injection. 1 125 Solution 3. 2 mL (10 mg) DEX sodium phosphate injectable 100 4 solution and 1 mL (5 mg) TRO hydrochloride injectable 75 solution were transferred to a 100 mL polyolefin bags and (mAU) filled with 0.9% sodium chloride injection. 3 50 2 5 Solution 4. 2mL(10mg)AZAhydrochlorideinjectablesolu- 25 tionwastransferredtoa100mLpolyolefinbagsandfilled with 0.9% sodium chloride injection. −20 0.0 2.0 4.0 6.0 8.0 10.0 12.0 15.0 2.5. Validation of the Method. The developed analytical (min) method was subjected to validation with respect to various Figure 2: HPLC chromatograms of AZA (1), GRA (2), TRO (3), parameters such as linearity, intra- and interday precision, OND (4), and DEX (5). accuracy, limit of quantification (LOQ), limit of detection (LOD), and reproducibility for each analyte. 2.6. Physicochemical Stability Study of the Infusion Samples. advantages over conventional UV detection. It enables peak The compatibility and stability studies of the infusion samples purity to be checked and simultaneous recording at the ∘ were performed at 25±0.5 C; all the solutions were protected wavelength of maximum absorbance. The absorption maxi- from light exposure and checked at predetermined times: 0, mum of DEX sodium phosphate, OND hydrochloride, GRA 2, 4, 8, 24, and 48 hours. At the specified times, the infusion hydrochloride, TRO hydrochloride, and AZA hydrochloride samples were examined for the changes in appearance and at 241, 310, 302, 285, and 302 nm was selected for detection. the pH value of the mixture was also determined in a digital 3.2. Linearity, Limit of Detection (LOD), and Limit of Crison phs-3c pH meter. Moreover, the concentrations of Quantitation (LOQ). Linearity was performed by preparing the drugs were determined at each analysis by the above mixed standard solutions of DEX sodium phosphate, OND described HPLC-DAD method. In the concentrations’ anal- hydrochloride, GRA hydrochloride, TRO hydrochloride, and ysis, 2 mL samples were collected from each polyolefin bag AZA hydrochloride at six concentration levels. The linearity and were diluted 1 : 5 in deionised water before injection into of detector response for DEX sodium phosphate, OND HPLC system so as to be within the range covered by the hydrochloride, GRA hydrochloride, TRO hydrochloride, and calibration curves.

Load more

  7

Copy Link